Genmab — Oktober 2019

[transalp]

:))

[E_L]

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's - up 30%+ pre market....

[Helge_LarsenPI-redaktør]

Bergen Bio stiger 25% lige nu.
Administration (FDA) has approved Fast Track Designation for bemcentinib for the
treatment of elderly patients with acute
myeloid leukaemia (AML) whose disease
has relapsed. There are currently no marketed drugs specifically approved for
all relapsed AML patients, representing a significant unmet medical need.
BerGenBio has ongoing phase 2 trials in this indication and plans to seek
regulatory advice from the FDA and European Medicines Agency (EMA) to determ

[Helge_LarsenPI-redaktør]

ine
the optimal regulatory path for bemcentinib in relapsed AML. https://classic.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=219668008&sourcecode=ob

[Helge_LarsenPI-redaktør]

Nu + 32% . Er vi glade Sukkeralf.

[Plimsoller]

Jeg er gået all-in på Bergen Bio i Børsen's aktiespil, men desværre købte jeg for tidligt

[Helge_LarsenPI-redaktør]

Bergenbio-byks etter nyhet om rask prosess i USA

Bergenbio-byks etter nyhet om rask prosess i USA

E24 (e24.no)

[mobbyduck1]

@helgelarsen. det er vel lidt svært at være glad for at være bergen aktionær stadigvæk, faldt fra kurs 50 til kurs 10 i lige linje på et år, så kurs 20 er vel kun et lille plaster på såret

[mobbyduck1]

sådan føl
es det ihvertfald her

[Mcjean]

Han er nok mere glad for zymework måske?

[E_L]

amazing really how Biogen is up today almost 1,5x the total value of Genmab on a drug that isn't even filed yet...

[lahn1]

EL - said about Zymeworks, but applies to BergenBio as well. The analyst believes Investors "need to identify promising assets ever earlier in the valuation cycle to consistently get an edge with a large enough position to matter.

[lahn1]

Add to that, that Bergenbio is traded in Oslo

[Bulder]

Stort set al pharma, biotek, medico stiger i dag, så vidt jeg kan se.

[E_L]

@lahn1 easier said then done... if you take Aducanumab as example; it failed in march and Biogen crashed, and look what happens today... Wonder what that analyst had said about that lol

[Solsen]

I belive we could se ATH this year. Dataset on CD20/CD3 and Andromeda could give the boost that is needed.

[lahn1]

you are right. Predicting winners has not become any easier, but if you want to get in at attractive prices, one might have to take more risk today than previously, I guess.

[E_L]

sure @Solsen, and if other biotech news can get Bio out of it's 4+ years of depression that can help as well

[E_L]

I actually think Q4 Dara numbers will be very good and will impact price before the end of the year - before WE actually know any sales numbers, larger investors will figure it out...

[Solsen]

Perhaps prescriptions from oct and nov can do it